Broz ML, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 2014;26(5):638–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roberts EW, et al. Critical role for CD103+/CD141+ dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell. 2016;30(2):324–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salmon H, et al. Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity. 2016;44(4):924–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gardner A, Ruffell B. Dendritic cells and cancer immunity. Trends Immunol. 2016;37(12):855–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Veglia F, Gabrilovich DI. Dendritic cells in cancer: the role revisited. Curr Opin Immunol. 2017;45:43–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227–42.

Article  PubMed  PubMed Central  Google Scholar 

Derakhshani A, et al. Regulation of CTLA-4 and PD-L1 expression in relapsing-remitting multiple sclerosis patients after treatment with fingolimod, IFNβ-1α, glatiramer acetate, and dimethyl fumarate drugs. Journal of Personalized Medicine. 2021;11(8):721.

Article  PubMed  PubMed Central  Google Scholar 

Park J, Kwon M, Shin E-C. Immune checkpoint inhibitors for cancer treatment. Arch Pharmacal Res. 2016;39:1577–87.

Article  CAS  Google Scholar 

Wang W, et al. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25Hi regulatory T cells. Int Immunol. 2009;21(9):1065–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Derakhshani A, et al. Cytotoxic T-lymphocyte antigen-4 in colorectal cancer: another therapeutic side of capecitabine. Cancers. 2021;13(10):2414.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wei T, et al. Increased expression of immunosuppressive molecules on intratumoral and circulating regulatory T cells in non-small-cell lung cancer patients. Am J Cancer Res. 2015;5(7):2190.

CAS  PubMed  PubMed Central  Google Scholar 

Sakuishi K, et al. TIM3+ FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology. 2013;2(4): e23849.

Article  PubMed  PubMed Central  Google Scholar 

Fuhrman CA, et al. Divergent phenotypes of human regulatory T cells expressing the receptors TIGIT and CD226. J Immunol. 2015;195(1):145–55.

Article  CAS  PubMed  Google Scholar 

Ocampo Daza D, Lewicka M, Larhammar D. The oxytocin/vasopressin receptor family has at least five members in the gnathostome lineage, inclucing two distinct V2 subtypes. Gen Comp Endocrinol. 2012;175(1):135–43.

Article  CAS  PubMed  Google Scholar 

Antoni FA. Magnocellular vasopressin and the mechanism of “glucocorticoid escape.” Front Endocrinol (Lausanne). 2019;10:422.

Article  PubMed  Google Scholar 

Antoni FA. Novel ligand specificity of pituitary vasopressin receptors in the rat. Neuroendocrinology. 1984;39(2):186–8.

Article  CAS  PubMed  Google Scholar 

Roper J, et al. The vasopressin Avpr1b receptor: molecular and pharmacological studies. Stress. 2011;14(1):98–115.

Article  CAS  PubMed  Google Scholar 

Hou, D., et al. Model roles of the hypothalamo-neurohypophysial system in neuroscience study. 2016.

Sims CA, et al. Supplemental arginine vasopressin during the resuscitation of severe hemorrhagic shock preserves renal mitochondrial function. PLoS ONE. 2017;12(10):e0186339.

Article  PubMed  PubMed Central  Google Scholar 

Wiedermann FJ, et al. Effects of arginine vasopressin on migration and respiratory burst activity in human leukocytes. Open Med (Wars). 2018;13:122–9.

Article  CAS  PubMed  Google Scholar 

Bell J, et al. Identification and characterization of [125I]arginine vasopressin binding sites on human peripheral blood mononuclear cells. Life Sci. 1993;52(1):95–105.

Article  CAS  PubMed  Google Scholar 

Budnik B, et al. SCoPE-MS: mass spectrometry of single mammalian cells quantifies proteome heterogeneity during cell differentiation. Genome Biol. 2018;19(1):161.

Article  PubMed  PubMed Central  Google Scholar 

Sawchenko PE, Swanson LW. The organization of forebrain afferents to the paraventricular and supraoptic nuclei of the rat. J Comp Neurol. 1983;218(2):121–44.

Article  CAS  PubMed  Google Scholar 

Block LH, et al. 125I-8-L-arginine vasopressin binding to human mononuclear phagocytes. J Clin Invest. 1981;68(2):374–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Walters MR. Newly identified actions of the vitamin D endocrine system. Endocr Rev. 1992;13(4):719–64.

CAS  PubMed  Google Scholar 

Xu H, et al. 1,25-Dihydroxyvitamin D3 exerts opposing effects to IL-4 on MHC class-II antigen expression, accessory activity, and phagocytosis of human monocytes. Scand J Immunol. 1993;38(6):535–40.

Article  CAS  PubMed  Google Scholar 

Girasole G, et al. Augmentation of monocyte chemotaxis by 1 alpha,25-dihydroxyvitamin D3. Stimulation of defective migration of AIDS patients. J Immunol. 1990;145(8):2459–64.

Article  CAS  PubMed  Google Scholar 

Adorini L. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting autoimmune diabetes. Ann N Y Acad Sci. 2003;987:258–61.

Article  CAS  PubMed  Google Scholar 

Mathieu C, Adorini L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med. 2002;8(4):174–9.

Article  CAS  PubMed  Google Scholar 

Barragan M, Good M, Kolls JK. Regulation of dendritic cell function by vitamin D. Nutrients. 2015;7(9):8127–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Enioutina EY, Bareyan D, Daynes RA. Vitamin D3-mediated alterations to myeloid dendritic cell trafficking in vivo expand the scope of their antigen presenting properties. Vaccine. 2007;25(7):1236–49.

Article  CAS  PubMed  Google Scholar 

Opelz G. Effect of the maintenance immunosuppressive drug regimen on kidney transplant outcome. Transplantation. 1994;58(4):443–6.

Article  CAS  PubMed